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Abstract
Obesity is a very common health problem in almost all societies. Although obesity 
is a problem especially in high-income or upper-middle-income countries, it is pre-
dicted that obesity will increase rapidly in the future in developing countries. Excess 
body weight is associated with an increased risk for many malignancies and its impact 
on cancer incidence and mortality is well established. The role of obesity in the 
pathogenesis of endometrial cancer has been proved. The incidence of endometrial 
cancer is increasing due to an increasing prevalence of obesity. Approximately 57% 
of endometrial cancers in the United States are thought to be attributable to being 
overweight and obese. The mechanisms underlying the relationship between obesity 
and endometrial cancer have not been fully defined, however adipokines are known 
to stimulate cell proliferation in endometrial carcinoma. By preventing obesity and 
reducing its prevalence, deaths from endometrial cancer can be reduced.
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1. Introduction
Obesity is a very common health problem in almost all societies. Although obesity 
is a problem especially in high-income or upper-middle-income countries, it is 
predicted that obesity will increase rapidly in the future in developing countries. The 
worldwide prevalence of obesity has more than doubled among women and tripled 
among men over the past four decades [1]. Excess body weight is associated with an 
increased risk for many malignancies and its impact on cancer incidence and mortal-
ity is well established [2]. This makes obesity an important public health problem. 
Despite clear evidence linking endometrial cancer and obesity, public awareness is 
poor [3, 4]. Weight, weight gain, and obesity account for about 20% of all cancer 
cases. Although the role of obesity in the pathogenesis of endometrial cancer has 
been proved, its importance in the esophagus, thyroid, colon, kidney, liver, mela-
noma, multiple myeloma, rectum, gallbladder, leukemia, lymphoma, and prostate in 
men and breast cancer in postmenopausal women is also demonstrated [5, 6].
Endometrial cancer is the most common female genital tract malignancy in 
high-income countries and the second most common gynecological cancer in low-
middle-income countries. Endometrial carcinoma is a histological diagnosis based 
on characteristic findings in an endometrial biopsy, curettage, or hysterectomy 
specimen. A woman’s lifetime risk of endometrial cancer in the general popula-
tion is 3%. The incidence peaks between the ages of 60 and 70, but less than 5% of 
cases emerge before age of 40. The incidence of endometrial cancer is increasing 
due to an increasing prevalence of obesity, decreased use of menopausal hormone 
therapy with progestins, increased prevalence of diabetes, and changes in repro-
ductive behavior (eg, nulliparity) [7, 8]. Most patients are diagnosed at an early 
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stage and therefore have a five-year survival rate of more than 90%. Unfortunately, 
approximately 30% of women have stage III or IV disease, with 5-year survival rates 
significantly worse than in early-stage patients, 60% and 20%, respectively [9].
The primary complaint is abnormal uterine bleeding in 70% to 90% of endome-
trial carcinoma cases [10]. Premenopausal patients with abnormal uterine bleeding 
have a lower risk of cancer than postmenopausal women with the same complaint. 
In patients younger than 45 years of age, abnormal uterine bleeding tends to be 
persistent and is more likely to occur if there is a history of unopposed estrogen 
exposure (eg. obesity, chronic anovulation). The emergence of endometrial carci-
noma in postmenopausal women requires evaluation of endogenous and exogenous 
estrogen sources because unopposed estrogen (estrogen therapy, obesity, selective 
estrogenic receptor modulators, some herbs, sex cord-stromal tumors) is a risk 
factor for the disease.
Endometrial carcinoma is sometimes discovered incidentally when a hysterec-
tomy is performed for benign disease. To minimize this coincidence and optimize 
the surgical procedure performed, patients with abnormal uterine bleeding should 
always undergo endometrial sampling before performing a hysterectomy, and the 
results should be evaluated to determine the extent of surgery before the operation. 
Occult uterine cancer risk is significantly associated with race/ethnicity, obesity, 
comorbidity, personal history of malignancy, and cause of hysterectomy [11].
Typically, a pelvic examination is usually normal in patients with early-stage 
endometrial carcinoma. In women with more advanced disease, the uterus can 
be palpated as larger and fixed for the age of the patient. With blind endometrial 
sampling, the sensitivity is 90% or higher. History of colorectal cancer, endometrial 
polyps, and morbid obesity are risk factors for false-negative endometrial sampling 
[12]. In case of high clinical suspicion, hysteroscopy and targeted lesion-directed 
biopsy can be performed to reduce the false-negative rate. It is important to repeat 
endometrial sampling to exclude endometrial hyperplasia or carcinoma, especially 
in patients with risk factors for malignancy (eg. obesity, chronic anovulation).
More than 90% of uterine cancers originate from the endometrium, with most 
of the remainder originating from the myometrial muscle or less frequently from the 
endometrial stroma [13]. Adenocarcinoma of the endometrium is the most common 
histological type. The prognosis of endometrial carcinoma is primarily determined by 
the stage, grade, and histology of the disease. Most patients have a favorable prognosis 
as the majority of the histological type is the endometrioid type and presents with 
early-stage disease. Serous and clear cell types and other uterine cancers are associated 
with poor prognosis. Most women with low-risk endometrial cancer die from another 
cause, and cardiovascular disease is the leading cause of death among endometrial 
cancer patients [14]. The endometrioid type is the subtype predominantly associ-
ated with obesity; however, more aggressive subtypes (such as serous, clear cell, and 
carcinosarcoma) have recently been stated to increase with obesity [15].
Endometrial carcinomas are divided into two categories that differ in incidence, 
response to hormones, clinicopathological features, and risk factors [16, 17]. However, 
this approach does not adequately address the complexity of these neoplasms. Because 
25% of high-grade endometrioid carcinomas progress like serous carcinomas [18].
Type 1: It accounts for about 80 percent of endometrial carcinomas. Includes 
tumors with grade 1 or 2 endometrioid histology; It may result from intraepithelial 
neoplasm (atypical and/or complex endometrial hyperplasia), typically has a favor-
able prognosis, is estrogen-induced, and responsive to progestins on therapy. While 
estrogen excess is important in its etiology, unexposure to progesterone is probably 
equally important. The increasing prevalence of obesity, decreased use of meno-
pausal hormone therapy with progestins, and decreased propensity to delivery in 
women explain the increasing prevalence of type 1 endometrial carcinoma.
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Type 2: Accounts for 10 to 20 percent of endometrial carcinomas. Includes grade 
3 endometrioid tumors as well as histological types of non-endometrioid types: 
serous, clear cell, mucinous, squamous, transitional cell, mesonephric, and undif-
ferentiated. These patients generally have lower body mass indexes and are older 
than type 1 patients. These neoplasms are insensitive to estrogen, often occur in the 
atrophic endometrium, and have a poor prognosis. The reason for the increased 
incidence of type 2 neoplasms is unknown.
The Cancer Genome Atlas (TCGA) Research Network has significantly 
improved our understanding of the molecular level of endometrial cancer and 
introduced not two but four molecular subtypes [18];
1. POLE (ultra mutated) tumors,
2. Microsatellite unstable tumors,
3. Tumors with high copy number, mostly with TP53 mutations,
4. The group remaining without these changes.
2. Risk factors for endometrial cancer
The main risk factor for type I (endometrioid) endometrial carcinoma is an 
excess of endogenous or exogenous estrogen that is not adequately opposed with 
progestin [19]. In a woman with a uterus, oral, transdermal, and vaginal systemic 
estrogen therapy without the administration of progestin results in a marked 
increased risk of developing endometrial premalignant lesions and endometrial 
carcinoma. Unopposed estrogen increases the risk of endometrial cancer by 2–10 
times [20]. Studies have reported an increased risk of endometrial cancer in patients 
using estrogen alone, depending on the dose and duration of use [21–23]. The risk 
of endometrial cancer in postmenopausal patients is estimated to be approximately 
1 in 1000; therefore, studies have shown that patients receiving unopposed estrogen 
have an increased absolute risk of up to 1 in 100 [24]. Other risk factors include 
tamoxifen therapy, chronic anovulation, obesity, nulliparity, early menarche, late 
menopause, ovarian granulosa cell tumor, Cowden syndrome, having a first-degree 
relative with endometrial cancer, history of pelvic radiotherapy, diabetes mellitus 
and hypertension, and Lynch syndrome. A history of breast cancer is a risk factor 
for the development of endometrial cancer, partly because of the use of tamoxifen 
in the treatment of breast cancer, the increased risk of breast cancer in conditions 
such as obesity, and Cowden syndrome. As patients with hypertension and diabetes 
mellitus are generally obese, much of the risk these two comorbid conditions have 
in developing endometrial cancer may be attributable to obesity [25]. However, 
there are also studies stating that each has an independent risk factor [26, 27].
3. Obesity
Obesity is a chronic disease that is considered a global epidemic today. Obesity 
is defined by the World Health Organization (WHO) as excessive accumulation 
of fat in the body to the extent that it impairs health. According to WHO esti-
mates, 39% of adults worldwide were overweight and 13% were obese in 2016. 
Obesity is defined as an excess weight rather than excess fat, as it is impractical 
to determine body fat percentage. Based on the body mass index (BMI) of the 
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definition and grading of obesity, it is evaluated with the formula (BMI=Weight 
(kg)/Height (m2)). BMI provides a better estimate of total body fat compared 
to bodyweight alone [28]. According to the World Health Organization (WHO) 
standards, someone with a body mass index (BMI) >30 kg/m2 is classified as 
obese. Obesity classification according to body mass index in adults is dem-
ostrated in Table 1 [29–31]. According to the World Food Security and Nutrition 
Status 2019, obesity rates are increasing day by day in almost every country and 
the global adult obesity rate has reached 13.2% [32]. Today, overweight and 
obesity are considered to increase the overall health burden more than smoking. 
Obesity is associated with a significant increase in morbidity (including diabetes 
mellitus, hypertension, dyslipidemia, cardiovascular diseases, cerebrovascular 
accident, sleep apnea, and cancer) and mortality [33]. Weight loss reduces 
obesity-related morbidity. Due to the potential stigma risk of obesity, routine 
screening, diagnosis, and management are rare, and there is insufficient aware-
ness of the health problems caused by obesity in the population.
The type of obesity with increased waist circumference or waist/hip ratio 
is called central (abdominal, visceral, android, or male-type obesity) obesity. 
According to WHO, a waist circumference of 88 cm or more in women and 102 cm 
or more in men indicates the presence of central obesity. Patients with central obe-
sity have higher mortality rates [34] because these patients are at high risk for heart 
disease, diabetes, hypertension, dyslipidemia, and non-alcoholic fatty liver disease 
[34, 35]. Central obesity is a component of metabolic syndrome. The association 
of metabolic syndrome with endometrial cancer has also been reported [36, 37]. 
However, there is no data to suggest that outcomes can be improved with more 
effective management of associated medical conditions. In the Prospective Studies 
Collaboration analysis, in the upper BMI range (25 to 50 kg/m2), every 5 kg/m2 
increase in BMI is associated with coronary heart disease (CHD), stroke, diabetes, 
chronic kidney disease, and cancer (liver, kidney, breast, endometrial, prostate and 
colon) have been demonstrated to result in a significant increase in deaths [38].
Most cases of obesity are related to behaviors such as a sedentary lifestyle and 
increased calorie intake. Obesity develops with excessive fat accumulation in the body 
secondary to high energy intake. Energy homeostasis is impaired due to an increase in 
energy intake or a decrease in energy expenditure [39]. Interactions between genetic/
epigenetic factors and behavioral/social factors and chronic stress regulate energy 
balance. High-calorie diet, physical inactivity, sedentary lifestyle, and in addition, 
eating disorders accelerate the development of obesity. In addition, hypertrophy, 
hyperplasia and inflammation in adipocytes cause many changes in the structure 
of adipose tissue and the secretion of adipokines such as leptin, interleukin-6, and 
Underweight BMI <18.5 kg/m2
Normal weight BMI ≥18.5 to 24.9 kg/m2
Overweight BMI ≥25 to 29.9 kg/m2
Obesity BMI ≥30 kg/m2
Obesity class 1 BMI 30 to 34.9 kg/m2
Obesity class 2 BMI 35 to 39.9 kg/m2
Obesity class 3 BMI ≥40 kg/m2 (also referred to as severe, extreme, or massive 
obesity)
BMI, body mass index.
Table 1. 
Classification of body mass index.
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tumor necrosis factor-a. With the increasing prevalence of obesity, there is a growing 
awareness of its impact on cancers. Obesity has been defined as a risk factor affecting 
the severity of the disease and mortality in people with cancer.
4. The relationship between endometrial cancer and obesity
Obesity is known to increase the risk of endometrial cancer in women [40, 41]. 
Approximately 57% of endometrial cancers in the United States are thought to be 
attributable to being overweight and obese. The incidence of endometrial cancer 
increases as body mass index (BMI) increases [42]. More importantly, obesity and 
overweight can increase the likelihood of dying from cancer. A review of the litera-
ture states that most of the associations between adiposity indices and endometrial 
cancer are supported by strong or highly suggestive evidence. A review (IARC) 
from a comprehensive meta-analysis of weight, physical activity, and cancer 
incidence by the International Agency for Research on Cancer demonstrated that it 
is the cause of 39% of endometrial cancer cases [43].
The cause and effect relationship between obesity and endometrial cancer 
can be explained by 3 mechanisms; first; in obese patients, the adrenal glands 
secrete more androgen precursors for conversion to estrogen in peripheral tis-
sues. An androgen, androstenedione, (A) is converted to estrone (E1) mainly in 
peripheral adipose tissue, and this conversion is increased in adipose tissue of 
obese patients. Plasma SHBG levels that bind estradiol (E2) are reduced in obese 
subjects and therefore higher-than-normal amounts of serum estradiol are present 
in the circulation, thereby increasing the estrogenic stimulus in target tissues [44]. 
Proinflammatory cytokines such as tumor necrosis factor-a in obesity are associ-
ated with low plasma SHBG levels [45]. Obese patients also have changes in the 
concentration of insulin-like growth factors and their binding proteins and insulin 
resistance, all of which may contribute to an increased risk of endometrial cancer in 
these patients [46]. The triad of obesity, insulin resistance, and adipokine aberra-
tions is linked to cancer [47], since adipokines impair insulin signaling and contrib-
ute to insulin resistance [48]. Other mechanisms in pathophysiology are subclinical 
chronic low-grade inflammation, oxidative stress, and sex hormone biosynthesis 
[6]. Adipokine-mediated chronic inflammation and cellular stress cause genetic 
instability and DNA damage [42]. All of these mechanisms lead to endometrial 
hyperplasia and cancer. Despite all these conditions, obese patients who do not have 
metabolic problems seem to have an increased risk of endometrial cancer [49].
The mechanisms underlying the relationship between obesity and endometrial 
cancer have not been fully defined. However, estrogens and proinflammatory 
adipokines are known to stimulate cell proliferation in endometrial carcinoma. 
In addition to stimulating cell proliferation, estrogen also has mutagenic proper-
ties. Genotoxic metabolites of estrogen react with DNA and contribute to DNA 
breaks and genetic instability [50]. Although the role of estrogen metabolites in 
the pathogenesis of breast cancer is well defined, their role in the context of endo-
metrial cancer has not been fully understood. However, defects in DNA mismatch 
repair genes were detected in one-third of endometrial cancer cases. Visceral fat is 
a complex endocrine organ composed of adipocytes, preadipocytes, macrophages, 
stromal, nerve, and stem cells [42]. Adipokines secreted by these cells increase 
endometrial proliferation and promote tumor formation [51], even mesenchymal 
stem cells support tumor growth and progression [52, 53].
Cyclic secretion of ovarian estrogen and estrogen-induced cyclic secretion of 
insulin-like growth factor 1 (IGF1) in premenopausal women stimulates endome-
trial proliferation [54, 55]. In postmenopausal women, especially adipose tissue 
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is the main site of estrogen synthesis [56]. Aromatase enzyme, which provides 
estrogen synthesis from androgens, is mainly found in adipose tissue [57]. As body 
adiposity increases, the amount and activity of aromatase increases [58]. Steroid 
hormone synthesis from cholesterol and estrogen synthesis from androgens by 
aromatase enzyme is shown in Figure 1.
In a pooled analysis of individual patient data from 10 cohort and 14 case–con-
trol studies, including more than 14,000 endometrial cancer cases and more than 
35,000 controls, for type I endometrial cancer, by body mass index (BMI): over-
weight (BMI) 25.0 to <30.0 kg/m2) OR 1.5, OR 2.5 (30.0 to <35.0 kg/m2) for class 1 
obesity, OR 4.5 for class 2 obesity (35.0 to 39.9 kg/m2) and calculated as 7.1 for class 
3 obesity (≥40.0 kg/m2). For type 2 endometrial cancer, the ORs were calculated 
as 1.2 for overweight, 1.7 for class 1 obesity, 2.2 for class 2 obesity, and 3.1 for class 3 
obesity [59]. Higher BMI is associated with the development of endometrial cancer 
at a younger age (<45 years old) [60]. In another meta-analysis, body mass index 
and waist-to-hip ratio were associated with increased cancer risk in premenopausal 
women (RR 1.49 per 5 kg/m2; CI 1.39–1.61) and for total endometrial cancer (RR 
1.21 per 0.1 unit; CI 1.13–1.29), respectively [61].
Severely obese patients (BMI ≥40 kg/m2) who develop endometrial cancer are 
more likely to have a less aggressive histological subtype (endometrioid 87% vs. serous 
or clear cell 75%) compared to patients with BMI <30 kg/m2 [62]. Therefore, patients 
with severe obesity are more likely to present with stage I disease (77 versus 61%) or 
low-grade histology (44% vs. 24%), but severe obesity is associated with an increased 
risk of death in endometrial cancer patients [63, 64]. After being diagnosed with 
endometrial cancer, being obese indicates worse outcomes. Obesity has a negative 
effect on all-cause mortality. A retrospective study found that morbidly obese women 
with early-stage disease had higher mortality rates compared with women with a nor-
mal body mass index, accounting for 67% of these deaths. It has been determined that 
there are obesity-related causes unrelated to cancer [65]. Increased mortality may be 
due to sustained stimulation of metastatic cells by endogenous estrogen or may result 
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After obese women are diagnosed with endometrial cancer, clinical management 
strategies can be complex. As the operations of obese patients are technically more 
difficult it takes a longer time than normal-weight individuals. Since these patients 
also have many co-morbid medical problems, both perioperative and postoperative 
complication rates are increased. Even though the patients have early-stage cancer, 
they may not be able to be operated on due to concomitant systemic diseases such as 
cardiovascular and diabetes mellitus, and they may have to undergo primary radio-
therapy. Robotic surgery may provide an advantage over conventional laparoscopy in 
such patients [68, 69].
Meta-analyses show that increased physical activity reduces the risk of endome-
trial cancer [70–72]. Exercise may provide moderate protection against endometrial 
cancer [73]. Physical activity benefits by reducing obesity and making positive 
changes in immune function, endogenous sexual and metabolic hormone levels, 
and growth factors [74]. Losing weight through lifestyle changes such as diet and 
physical activity or bariatric surgery can reduce obesity. Bariatric surgery has been 
associated with a 50% to 80% reduction in the occurrence of endometrial cancer in 
a meta-analysis of controlled trials [75, 76]. Obesity-related hormonal and metabolic 
disorders and drugs aimed at correcting insulin resistance can also be used as a pre-
vention strategy. Losing weight has health benefits beyond protecting the endome-
trium. Preventing or treating obesity can provide significant lifelong health benefits. 
Public health interventions may be beneficial to reduce the incidence of endometrial 
cancer in the community. Obese patients should receive counseling about health 
risks, lifestyle changes, obesity treatment options, and risk factor reduction.
5. Conclusion
By preventing obesity and reducing its prevalence, deaths from endometrial 
cancer can be reduced. Prevention strategies should focus on changing the envi-
ronmental and lifestyle risk factors that cause endometrial cancer. General lifestyle 
recommendations include being physically active and maintaining a healthy weight. 
Healthy weight is considered a risk reducer and has a positive effect on blood pres-
sure, glucose metabolism, cardiac and vascular function. Therefore, reducing obesity 
reduces morbidity and mortality from endometrial cancer. More public awareness is 
needed regarding the cause and effect relationship between obesity and endometrial 
cancer. Public health education including obesity prevention is of great importance.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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